Definium Therapeutics Insider Mark Sullivan Sells Shares
Mark Sullivan, Chief Legal Officer of Definium Therapeutics, sold 13,008 shares on June 25, 2026.
Key Points
- On June 25, 2026, Mark Sullivan, Chief Legal Officer of Definium Therapeutics, sold 13,008 shares at an average price of $45.03, totaling $585,750.
- Shares of Definium Therapeutics, Inc. (NasdaqGS:DFTX) traded near $44.95 on Saturday, with a market cap of $5.97 billion and a 52-week high of $47.01.
- Analysts, including Jones Trading and Baird, maintain a 'buy' rating on DFTX, with price targets ranging from $38 to $74.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Mark Sullivan, the Chief Legal Officer of Definium Therapeutics, Inc. (NasdaqGS:DFTX), sold 13,008 shares of the company on June 25, 2026. The shares were sold at an average price of $45.03, bringing the total transaction value to approximately $585,750. This sale was part of a pre-planned trading arrangement under Rule 10b5-1.
Insider Buying and Selling at Definium Therapeutics, Inc.
Several key insiders at Definium Therapeutics were active in the market on June 25, 2026. Robert Barrow, the CEO, sold 29,208 shares; Daniel Karlin, the Chief Medical Officer, sold 10,035 shares; and Matthew Wiley, the Chief Commercial Officer, sold 2,867 shares. Each transaction was executed at an average price of $45.03 and was part of a planned trading strategy. Additionally, Daniel Karlin made a significant purchase of 100,000 shares on June 22, 2026, outside of any planned arrangement.
Other Institutional Activity in Definium Therapeutics
BlackRock, Inc. opened a new position in Definium Therapeutics, acquiring 8,480,230 shares valued at about $160.28 million. Similarly, Avoro Capital Advisors LLC initiated a stake with 5,000,000 shares worth approximately $94.5 million. Driehaus Capital Management LLC reduced its holdings by 625,313 shares, now holding 5,911,889 shares valued at $111.73 million, marking a 9.6% decrease.
Definium Therapeutics, Inc. Stock Up 9.7%
Shares of Definium Therapeutics, Inc. traded near $44.95 on Saturday. The company has a market capitalization of approximately $5.97 billion. With a beta of 2.378, the stock shows higher volatility compared to the market. It has a 52-week low of $6.40 and a high of $47.01. The company's forward P/E ratio is not meaningful as it is currently not profitable, and it has a current ratio of 4.69, indicating strong liquidity.
$DFTX stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On June 24, 2026, Jones Trading maintained a 'buy' rating on Definium Therapeutics with a price target of $74. Baird and Needham also sustained their 'buy' ratings with targets of $57 and $50, respectively, on June 23, 2026. The consensus among analysts is a 'strong buy', with an average target price of $56 across 15 opinions.
About Definium Therapeutics
Definium Therapeutics, Inc. is a healthcare company focused on biotechnology, headquartered in New York, NY. It develops innovative treatments for brain health disorders. The company's lead products include DT120, which is in phase 3 trials for anxiety and depression, and DT402, in phase 2a trials for autism spectrum disorder. Led by CEO Robert Barrow, Definium employs around 105 people.
Bottom Line
Mark Sullivan's recent stock sale is part of his planned trading strategy, reflecting routine insider activity at Definium Therapeutics. The company's shares are trading near their 52-week high, showing strong market interest despite current unprofitability. Analysts remain optimistic, maintaining 'buy' ratings with price targets suggesting potential upside.
Get Definium Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $DFTX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.